Evolent Health, Inc (NYSE:EVH – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the fifteen research firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $17.2143.
EVH has been the topic of a number of recent research reports. Truist Financial increased their price objective on Evolent Health from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, July 17th. BTIG Research restated a “buy” rating and issued a $20.00 target price on shares of Evolent Health in a research note on Tuesday. Stephens restated an “equal weight” rating and issued a $9.00 target price on shares of Evolent Health in a research note on Wednesday, September 24th. JMP Securities restated a “market outperform” rating and issued a $13.00 target price on shares of Evolent Health in a research note on Friday, June 20th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Evolent Health in a research note on Saturday, September 27th.
Check Out Our Latest Stock Report on Evolent Health
Hedge Funds Weigh In On Evolent Health
Evolent Health Stock Performance
Shares of EVH opened at $8.20 on Friday. The stock’s 50-day simple moving average is $9.17 and its 200 day simple moving average is $9.43. The stock has a market capitalization of $963.23 million, a price-to-earnings ratio of -5.09 and a beta of 0.66. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.01 and a current ratio of 1.01. Evolent Health has a 52-week low of $7.06 and a 52-week high of $27.42.
Evolent Health (NYSE:EVH – Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The technology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.20). The company had revenue of $444.33 million for the quarter, compared to analysts’ expectations of $459.43 million. Evolent Health had a positive return on equity of 1.83% and a negative net margin of 5.94%.The business’s revenue for the quarter was down 31.3% on a year-over-year basis. During the same period last year, the company posted $0.30 EPS. Evolent Health has set its Q3 2025 guidance at EPS. Research analysts forecast that Evolent Health will post 0.08 EPS for the current fiscal year.
Evolent Health Company Profile
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.
Read More
- Five stocks we like better than Evolent Health
- Health Care Stocks Explained: Why You Might Want to Invest
- After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught?
- What is diluted earnings per share (Diluted EPS)?
- Alphabet: After Its Best Quarter in Decades, Is It Time to Buy?
- Quiet Period Expirations Explained
- Forget Airlines—These Trucking Stocks Are Shifting Into High Gear
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.